GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genfit SA (NAS:GNFT) » Definitions » EV-to-FCF

GNFT (Genfit) EV-to-FCF : (As of Dec. 14, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Genfit EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Genfit's Enterprise Value is $197.09 Mil. Genfit's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil. Therefore, Genfit's EV-to-FCF for today is .

The historical rank and industry rank for Genfit's EV-to-FCF or its related term are showing as below:

GNFT' s EV-to-FCF Range Over the Past 10 Years
Min: -90.96   Med: -10.94   Max: 0.64
Current: -3.19

During the past 13 years, the highest EV-to-FCF of Genfit was 0.64. The lowest was -90.96. And the median was -10.94.

GNFT's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 8.19 vs GNFT: -3.19

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-14), Genfit's stock price is $3.8199. Genfit's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.455. Therefore, Genfit's PE Ratio (TTM) for today is At Loss.


Genfit EV-to-FCF Historical Data

The historical data trend for Genfit's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genfit EV-to-FCF Chart

Genfit Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.92 -1.74 0.31 -1.82 -2.91

Genfit Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.82 - - -2.91 -

Competitive Comparison of Genfit's EV-to-FCF

For the Biotechnology subindustry, Genfit's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genfit's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genfit's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Genfit's EV-to-FCF falls into.



Genfit EV-to-FCF Calculation

Genfit's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=197.091/0
=

Genfit's current Enterprise Value is $197.09 Mil.
Genfit's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genfit  (NAS:GNFT) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Genfit's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.8199/-0.455
=At Loss

Genfit's share price for today is $3.8199.
Genfit's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.455.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Genfit EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Genfit's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Genfit Business Description

Traded in Other Exchanges
Address
Parc Eurasante, 885, Avenue Eugene Avinee, Loos, FRA, 59120
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.